Switch of CD4+ T cell differentiation from Th2 to Th1 by treatment with cathepsin B inhibitor in experimental leishmaniasis.
When activated, CD4+ T helper cells differentiate functionally into one of two subsets, Th1 or Th2. Before the Th differentiation, Ags must be processed into peptide epitopes and presented to CD4+ T cells in association with MHC class II molecules. However, the proteases responsible for this Ag processing have not been well defined. When BALB/c mice susceptible to infection with Leishmania major were treated with a specific inhibitor (CA074) of cathepsin B, a lysosomal cysteine protease that digests exogenous antigenic proteins, those mice acquired resistance against infection with L. major and showed the shift of immune responses from Th2 to Th1; that is, they produced specific IgG2a Ab and generated IFN-gamma in contrast to untreated and infected mice that produced IgG1 and IgE and generated IL-4. CA074 interfered with the digestion of L. major Ags with lysosomal enzymes in vivo as well as in vitro. However, this inhibitor did not show any direct influence on the growth of L. major and the functions of T cells stimulated with anti-CD3 Ab. These findings indicate that cathepsin B inhibitor could switch CD4+ T cell differentiation from Th2 to Th1, suggesting that the alteration in Ag processing modulates the polarity of Th differentiation.
Maekawa
Y
Y
Department of Parasitology and Immunology, University of Tokushima School of Medicine, Japan.
Himeno
K
K
Ishikawa
H
H
Hisaeda
H
H
Sakai
T
T
Dainichi
T
T
Asao
T
T
Good
R A
RA
Katunuma
N
N
D000818:Animals; D000953:Antigens, Protozoan / Q000378:metabolism; D002401:Cathepsin B / Q000037:antagonists & inhibitors*; D002454:Cell Differentiation / Q000187:drug effects / Q000276:immunology; D015853:Cysteine Proteinase Inhibitors / Q000494:pharmacology*; D004151:Dipeptides / Q000494:pharmacology; D004789:Enzyme Activation / Q000187:drug effects; D005260:Female; D007113:Immunity, Innate / Q000187:drug effects; D007136:Immunoglobulins / Q000097:blood; D016130:Immunophenotyping; D018320:Leishmania major / Q000187:drug effects / Q000276:immunology*; D016773:Leishmaniasis, Cutaneous / Q000201:enzymology / Q000276:immunology* / Q000517:prevention & control; D008198:Lymph Nodes / Q000187:drug effects / Q000201:enzymology; D008247:Lysosomes / Q000276:immunology / Q000378:metabolism; D051379:Mice; D008807:Mice, Inbred BALB C; D008811:Mice, Inbred DBA; D016513:Mice, SCID; D012008:Recurrence; D013154:Spleen / Q000276:immunology / Q000378:metabolism; D018417:Th1 Cells / Q000166:cytology* / Q000187:drug effects / Q000201:enzymology; D018418:Th2 Cells / Q000166:cytology* / Q000187:drug effects / Q000201:enzymology
D000953:Antigens, Protozoan; D015853:Cysteine Proteinase Inhibitors; D004151:Dipeptides; D007136:Immunoglobulins; C068250:N-(3-propylcarbamoyloxirane-2-carbonyl)-isoleucyl-proline; D002401:Cathepsin B